Posizolid: Difference between revisions

Posizolid
Clinical data
Other names	AZD2563
ATC code	none;
Identifiers
	IUPAC name (5R)-3-[4-[1-[(2S)-2,3-Dihydroxypropanoyl]-3,6-dihydro-2H-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one;
CAS Number	252260-02-9 ;
PubChem CID	213049;
ChemSpider	184741 ;
UNII	82V2M8K24R;
CompTox Dashboard (EPA)	DTXSID40870284 DTXSID00948079, DTXSID40870284 ;
ECHA InfoCard	100.234.485
Chemical and physical data
Formula	C21H21F2N3O7
Molar mass	465.40 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(CC3=CC(F)=C(C4=CCN(C([C@@H](O)CO)=O)CC4)C(F)=C3)C[C@H](OC2=NOC=C2)O1;
	InChI InChI=1S/C21H21F2N3O7/c22-15-7-13(26-9-14(33-21(26)30)11-31-18-3-6-32-24-18)8-16(23)19(15)12-1-4-25(5-2-12)20(29)17(28)10-27/h1,3,6-8,14,17,27-28H,2,4-5,9-11H2/t14-,17+/m1/s1 ; Key:HBUJYEUPIIJJOS-PBHICJAKSA-N ;
	(what is this?) (verify)

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 04:40, 5 June 2016

Posizolid is an oxazolidinone antibiotic under investigation by AstraZeneca for the treatment of bacterial infections. At a concentration of 2 mg/L it inhibited 98% of all Gram-positive bacteria tested in vitro.^[1]

References

^ Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. (2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–254. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. (2004). "AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro". Clinical Microbiology and Infection. 10 (3): 247–254. doi:10.1111/j.1198-743X.2004.00770.x. PMID 15008947.

[1]

@@ Line 15: / Line 15: @@
 | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
 | legal_status =
 | routes_of_administration =
 <!--Pharmacokinetic data-->
@@ Line 22: / Line 22: @@
 | metabolism =
 | elimination_half-life =
 | excretion =
 <!--Identifiers-->
@@ Line 49: / Line 49: @@
 }}
-'''Posizolid''' is an [[oxazolidinone]] [[antibiotic]] under investigation by [[AstraZeneca]] for the treatment of bacterial infections.  At a concentration of 2 mg/L it inhibited 98% of all [[Gram-positive bacteria]] tested [[in vitro]].<ref>{{cite journal | author = Wookey, A.; Turner, P. J.; Greenhalgh, J. M.; Eastwood, M.; Clarke, J.; Sefton, C. | title = AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro | journal = Clinical Microbiology and Infection  | year = 2004 | volume =  10 | issue = 3 | pages = 247–254 | pmid=15008947 | doi = 10.1111/j.1198-743X.2004.00770.x}}</ref>
+'''Posizolid''' is an [[oxazolidinone]] [[antibiotic]] under investigation by [[AstraZeneca]] for the treatment of bacterial infections.  At a concentration of 2&nbsp;mg/L it inhibited 98% of all [[Gram-positive bacteria]] tested [[in vitro]].<ref>{{cite journal |author1=Wookey, A. |author2=Turner, P. J. |author3=Greenhalgh, J. M. |author4=Eastwood, M. |author5=Clarke, J. |author6=Sefton, C. | title = AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro | journal = Clinical Microbiology and Infection  | year = 2004 | volume =  10 | issue = 3 | pages = 247–254 | pmid=15008947 | doi = 10.1111/j.1198-743X.2004.00770.x}}</ref>
 ==References==
 {{reflist}}
-{{antibiotic-stub}}
 {{Protein synthesis inhibitor antibiotics}}
@@ Line 65: / Line 63: @@
 [[Category:Amides]]
 [[Category:Diols]]
+{{antibiotic-stub}}